Edition:
United States

Becton Dickinson and Co (BDX)

BDX on New York Consolidated

182.02USD
21 Feb 2017
Change (% chg)

$1.12 (+0.62%)
Prev Close
$180.90
Open
$181.50
Day's High
$182.65
Day's Low
$179.91
Volume
943,721
Avg. Vol
1,111,954
52-wk High
$182.65
52-wk Low
$144.73

BDX

Chart for BDX

About

Becton, Dickinson and Company (BD) is a global medical technology company engaged in the development, manufacture and sale of a range of medical supplies, devices, laboratory equipment and diagnostic products. The Company operates through two segments: BD Medical and BD Life Sciences. The BD Medical segment produces an array of... (more)

Overall

Beta: 1.04
Market Cap(Mil.): $38,738.42
Shares Outstanding(Mil.): 212.83
Dividend: 0.73
Yield (%): 1.60

Financials

  BDX Industry Sector
P/E (TTM): 30.24 34.21 29.32
EPS (TTM): 6.02 -- --
ROI: 6.34 12.42 13.03
ROE: 17.67 14.41 14.17

BRIEF-Becton Dickinson announces early access program for BD Resolve single-cell analysis platform

* BD announces early access program for bd resolve single-cell analysis platform

Feb 13 2017

BRIEF-Retractable Technologies seeks review of decision in case against Becton Dickinson

* Retractable Technologies - On Jan 31, Co filed a petition for a writ of certiorari with Supreme Court of the United States

Feb 08 2017

BRIEF-Becton Dickinson Q1 earnings per share $2.58

* Becton dickinson and co says raising expected full fiscal year 2017 adjusted diluted earnings per share to $9.70 to $9.80

Feb 02 2017

BRIEF-Becton Dickinson says PleurX catheter system receives FDA 510(k) clearance

* PleurX catheter system receives FDA 510(k) clearance for specific non-malignant recurrent pleural effusions Source text for Eikon: Further company coverage:

Jan 23 2017

Becton Dickinson wins reversal of $340 million syringe award

A federal appeals court on Friday threw out an antitrust verdict that ordered medical device maker Becton Dickinson and Co to pay rival Retractable Technologies Inc $340 million in damages over its marketing of safety syringes.

Dec 02 2016

BRIEF-Becton Dickinson board increases dividend

* Declared a quarterly dividend of $0.73 per common share, an increase of 10.6 percent from previous quarter Source text for Eikon: Further company coverage:

Nov 21 2016

BRIEF-Becton, Dickinson and Co announces tender offers for outstanding debt securities

* Becton, Dickinson and Company announces tender offers for outstanding debt securities

Nov 16 2016

BRIEF-Becton Dickinson launches syringe for use with Humulin R U-500 insulin

* BD launches first syringe designed for use with Humulin R U-500 insulin Source text for Eikon: Further company coverage: (Bangalore.newsroom@thomsonreuters.com)

Nov 08 2016

BRIEF-BD reports results for Q4 provides full-year fiscal 2017 guidance

* Becton Dickinson and Co - expects full fiscal year 2017 revenues to decrease 3.0 to 3.5 percent

Nov 03 2016

BRIEF-BD says Max Vaginal Panel receives FDA market authorization for test

* Bd max vaginal panel receives fda market authorization to detect most common causes of vaginal infections Source text for Eikon: Further company coverage:

Oct 31 2016

More From Around the Web

Earnings vs. Estimates